Treatment of early Parkinson's disease. Part 2.
The management of early Parkinson's disease (PD) involves the treatment of motor symptoms, and, increasingly, non-motor symptoms. Given the fast pace of clinical research in PD, clinicians are faced with the challenge of integrating the latest findings into the ongoing care of individual PD patients. Part 1 of this 2-part article reviews efficacy and safety data for the newest PD treatment options, as well as for established therapies. Part 2 of the article, presented here, reviews key data relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms.
Simuni
Tanya
T
Department of Neurology, Northwestern University, Parkinson's Disease and Movement Disorders Center, Chicago, Ill, USA. tsimuni@nmff.org
Lyons
Kelly E
KE
Pahwa
Rajesh
R
Hauser
Robert A
RA
Comella
Cynthia
C
Elmer
Lawrence
L
Weintraub
Daniel
D
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000188:drug therapy; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D000857:Olfaction Disorders / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013997:Time Factors
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D007980:Levodopa